CH
MRNA icon

Canton Hathaway’s Moderna MRNA Stock Holding History

Canton Hathaway’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.1K Hold
601
– – 0.01% 219
2026
Q1 		$30.5K Buy
+601
New +$28K 0.01% 229
2025
Q1 		– Sell
-601
Closed -$25K – 282
2024
Q4 		$25K Hold
601
– – 0.01% 219
2024
Q3 		$40K Sell
601
-820
-58% -$75.3K 0.01% 182
2024
Q2 		$169K Buy
1,421
+820
+136% +$104K 0.05% 99
2024
Q1 		$64K Hold
601
– – 0.02% 138
2023
Q4 		$60K Sell
601
-370
-38% -$31.1K 0.02% 147
2023
Q3 		$100K Buy
971
+370
+62% +$41.3K 0.03% 111
2023
Q2 		$73K Hold
601
– – 0.02% 127
2023
Q1 		$92K Sell
601
-730
-55% -$120K 0.03% 113
2022
Q4 		$239K Buy
1,331
+730
+121% +$119K 0.08% 84
2022
Q3 		$71K Hold
601
– – 0.03% 133
2022
Q2 		$86K Hold
601
– – 0.03% 130
2022
Q1 		$104K Hold
601
– – 0.03% 131
2021
Q4 		$153K Hold
601
– – 0.04% 129
2021
Q3 		$231K Sell
601
-200
-25% -$73.8K 0.07% 105
2021
Q2 		$188K Hold
801
– – 0.06% 103
2021
Q1 		$105K Buy
+801
New +$116K 0.03% 132
2020
Q2 		– Sell
-8,380
Closed -$251K – 164
2020
Q1 		$251K Buy
8,380
+5,000
+148% +$115K 0.18% 54
2019
Q4 		$66K Buy
3,380
+140
+4% +$2.48K 0.03% 115
2019
Q3 		$52K Sell
3,240
-4,980
-61% -$73.6K 0.03% 118
2019
Q2 		$120K Buy
8,220
+3,610
+78% +$77.5K 0.07% 98
2019
Q1 		$93K Buy
4,610
+2,165
+89% +$40.2K 0.05% 106
2018
Q4 		$37K Buy
+2,445
New +$40.2K 0.02% 118

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Canton Hathaway's MRNA Position: Q2 2026 in Review

Canton Hathaway held its Moderna (MRNA) position steady in Q2 2026 at 601 shares worth $42.1K. The position accounts for 0.01% of the portfolio, ranked #219.

Canton Hathaway first reported a position in MRNA in Q4 2018 and has held it in 24 quarters since. The position peaked at $251K in Q1 2020. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Canton Hathaway held 601 shares of Moderna worth $42.1K as of Q2 2026.
  • Canton Hathaway left its Moderna share count unchanged in Q2 2026.
  • Moderna made up 0.01% of Canton Hathaway's portfolio in Q2 2026, its #219 holding.
  • Canton Hathaway first reported a position in Moderna in Q4 2018 and has held it in 24 quarters since.
  • Canton Hathaway's Moderna position peaked at $251K in Q1 2020.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Canton Hathaway's 13F filing for Q2 2026, filed 6 Aug 2026.